Sienna Biopharmaceuticals Inc (NASDAQ:SNNA)’s stock price traded down 73.6% on Tuesday . The stock traded as low as $0.15 and last traded at $0.18, 9,672,279 shares changed hands during mid-day trading. An increase of 2,500% from the average session volume of 371,940 shares. The stock had previously closed at $0.67.
Several equities analysts have recently weighed in on the stock. ValuEngine upgraded shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. BMO Capital Markets lowered their price objective on shares of Sienna Biopharmaceuticals to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Sienna Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $17.00.
The company’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $1.39. The company has a current ratio of 2.43, a quick ratio of 2.43 and a debt-to-equity ratio of 1.11. The stock has a market cap of $20.81 million, a P/E ratio of -0.05 and a beta of 2.82.
Large investors have recently modified their holdings of the company. Canada Pension Plan Investment Board bought a new position in shares of Sienna Biopharmaceuticals in the 2nd quarter worth approximately $26,000. A.R.T. Advisors LLC lifted its stake in shares of Sienna Biopharmaceuticals by 84.5% in the 2nd quarter. A.R.T. Advisors LLC now owns 32,653 shares of the company’s stock worth $28,000 after purchasing an additional 14,954 shares during the period. Citadel Advisors LLC lifted its stake in shares of Sienna Biopharmaceuticals by 152.3% in the 2nd quarter. Citadel Advisors LLC now owns 40,555 shares of the company’s stock worth $35,000 after purchasing an additional 24,480 shares during the period. Jane Street Group LLC bought a new position in shares of Sienna Biopharmaceuticals in the 2nd quarter worth approximately $50,000. Finally, Paloma Partners Management Co bought a new position in shares of Sienna Biopharmaceuticals in the 2nd quarter worth approximately $60,000. Hedge funds and other institutional investors own 45.87% of the company’s stock.
Sienna Biopharmaceuticals Company Profile (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: How are institutional investors different from individual investors?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.